Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Interstitial lung disease associated with Sjögren's syndrome: Management and prognosis

Carlos Roberto Ribeiro de Carvalho, MD, PhD
Daniel Deheinzelin, MD, PhD
Ronaldo A Kairalla, MD, PhD
Section Editor
Talmadge E King, Jr, MD
Deputy Editor
Helen Hollingsworth, MD


Sjögren's syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function and associated with lymphocytic infiltration of exocrine glands, especially the lacrimal and salivary glands. In addition to causing dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), SS can affect extraglandular organ systems including the skin, lung, heart, kidney, neural, and hematopoietic systems.

Respiratory complications of SS include airway mucosal dryness (also known as xerotrachea), a variety of interstitial lung diseases (ILDs), non-Hodgkin lymphomas, pleural thickening or effusion, and, rarely, thromboembolic disease or pulmonary hypertension.

The management and prognosis of interstitial lung disease in SS will be reviewed here. The clinical manifestations, classification, evaluation, and diagnosis of Sjögren's syndrome and its associated interstitial lung diseases are presented separately. (See "Clinical manifestations of Sjögren's syndrome: Exocrine gland disease" and "Clinical manifestations of Sjögren's syndrome: Extraglandular disease" and "Diagnosis and classification of Sjögren's syndrome" and "Pathogenesis of Sjögren's syndrome" and "Interstitial lung disease associated with Sjögren's syndrome: Clinical manifestations, evaluation, and diagnosis".)


Management strategies for Sjögren-associated lung diseases are empiric, since no controlled studies have been performed. We base the treatment approach on the identified lung pathology, and the severity of symptoms, physiologic impairment, and extent of radiographic disease. (See "Interstitial lung disease associated with Sjögren's syndrome: Clinical manifestations, evaluation, and diagnosis", section on 'Histopathology'.)

Sjögren-associated ILD without biopsy confirmation — Asymptomatic patients with mild interstitial lung disease (ILD) based on high resolution computed tomography (HRCT) and/or pulmonary function testing (PFTs) may prefer not to pursue a lung biopsy for histopathologic diagnosis. For these patients, we monitor symptoms, HRCT, and PFTs at 6 to 12 month intervals. If progressive disease is identified, we typically advise further evaluation to identify the specific histopathology. (See "Interstitial lung disease associated with Sjögren's syndrome: Clinical manifestations, evaluation, and diagnosis", section on 'Evaluation and diagnosis'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: May 26, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130:1489.
  2. Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154:794.
  3. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640.
  4. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008; 68:554.
  5. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007; 66:351.
  6. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72:1026.
  7. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.
  8. Hansen LA, Prakash UB, Colby TV. Pulmonary lymphoma in Sjögren's syndrome. Mayo Clin Proc 1989; 64:920.
  9. Deheinzelin D, de Carvalho CR, Tomazini ME, et al. Association of Sjögren's syndrome and sarcoidosis. Report of a case. Sarcoidosis 1988; 5:68.
  10. Shi JH, Liu HR, Xu WB, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration 2009; 78:377.
  11. Aerni MR, Vassallo R, Myers JL, et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008; 102:307.
  12. Borie R, Schneider S, Debray MP, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome. Respir Med 2011; 105:130.
  13. Song MK, Seol YM, Park YE, et al. Pulmonary nodular lymphoid hyperplasia associated with Sjögren's syndrome. Korean J Intern Med 2007; 22:192.
  14. Miyoshi S, Hamada H, Katayama H, et al. A case of pulmonary nodular lymphoid hyperplasia with a resected cavity, followed by spontaneous regression of the remaining lesions. Intern Med 2010; 49:1617.
  15. Abbondanzo SL, Rush W, Bijwaard KE, Koss MN. Nodular lymphoid hyperplasia of the lung: a clinicopathologic study of 14 cases. Am J Surg Pathol 2000; 24:587.
  16. Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001; 56:964.
  17. Rajagopala S, Singh N, Gupta K, Gupta D. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. Respirology 2010; 15:860.
  18. Suzuki H, Matsui K, Hirashima T, et al. Three cases of the nodular pulmonary amyloidosis with a longterm observation. Intern Med 2006; 45:283.
  19. Berk JL, O'Regan A, Skinner M. Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 2002; 23:155.
  20. Linstow M, Kriegbaum NJ, Backer V, et al. A follow-up study of pulmonary function in patients with primary Sjögren's syndrome. Rheumatol Int 1990; 10:47.
  21. Mialon P, Barthélémy L, Sébert P, et al. A longitudinal study of lung impairment in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1997; 15:349.
  22. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis 2000; 59:709.
  23. Nannini C, Jebakumar AJ, Crowson CS, et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013; 3:e003569.
  24. Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases. PLoS One 2013; 8:e73774.
  25. Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford) 2013; 52:173.
  26. Kokosi M, Riemer EC, Highland KB. Pulmonary involvement in Sjögren syndrome. Clin Chest Med 2010; 31:489.